Aclaris Therapeutics, Inc. (ACRS) 10-Year Financial Performance & Capital Metrics

ACRS • • Industrial / General

HealthcareDiagnostics & ResearchContract Research & Clinical Trial ServicesResearch Support Services

AboutAclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Show more

Revenue $19M -40.1%
EBITDA -$141M -46.3%
Net Income -$132M -49.3%
EPS (Diluted) -1.71 -34.6%
Gross Margin 85.09% +101.9%
EBITDA Margin -753.87% -144.1%
Operating Margin -758.18% -143.4%
Net Margin -705.48% -149.2%
ROE -84.46% -69.3%
ROIC -85.6% -58.7%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 88 (top 12%)
✓Strong 5Y sales CAGR of 34.7%
✓Trading at only 1.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 10.7% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y34.66%

3Y40.42%

TTM-41.87%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-282.88%

EPS CAGR

10Y-

5Y-

3Y-

TTM-164.88%

ROCE

10Y Avg-54.45%

5Y Avg-61.62%

3Y Avg-55.9%

Latest-79.92%

Peer Comparison

Research Support Services

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CRLCharles River Laboratories International, Inc.	11B	223.47	1117.35	-1.92%	-2.07%	-2.42%	4.56%	0.78
SHCSotera Health Company	5.5B	19.35	120.94	4.88%	4.82%	10.07%	0.82%	5.81
ISPCiSpecimen Inc.	4.22M	0.42	-0.02	-6.42%	-343.99%	-375.34%		0.09
NOTVInotiv, Inc.	19.59M	0.57	-0.27	4.54%	-13.38%	-50.45%		3.01
ACRSAclaris Therapeutics, Inc.	289.28M	2.67	-1.56	-40.09%	-9%	-117.97%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	1.68M	10.09M	4.23M	6.48M	6.76M	29.75M	31.25M	18.72M
Revenue Growth %	-	-	-	5%	-0.58%	0.53%	0.04%	3.4%	0.05%	-0.4%
Cost of Goods Sold+	90K	120K	1.21M	6.85M	4.05M	5.13M	4.71M	11.96M	18.08M	2.79M
COGS % of Revenue	-	-	0.72%	0.68%	0.96%	0.79%	0.7%	0.4%	0.58%	0.15%
Gross Profit+	-90K	-120K	476K	3.24M	172K	1.35M	2.05M	17.79M	13.17M	15.93M
Gross Margin %	-	-	0.28%	0.32%	0.04%	0.21%	0.3%	0.6%	0.42%	0.85%
Gross Profit Growth %	-	-0.33%	4.97%	5.81%	-0.95%	6.84%	0.52%	7.69%	-0.26%	0.21%
Operating Expenses+	20.67M	48.57M	72.9M	138.66M	92.73M	52.26M	91.77M	107.65M	110.53M	157.86M
OpEx % of Revenue	-	-	43.31%	13.74%	21.94%	8.06%	13.57%	3.62%	3.54%	8.43%
Selling, General & Admin	5.33M	15.09M	33.11M	75.65M	27.83M	20.53M	23.62M	25.13M	31.1M	22.2M
SG&A % of Revenue	-	-	19.67%	7.5%	6.58%	3.17%	3.49%	0.84%	1%	1.19%
Research & Development	15.34M	33.48M	39.79M	63.01M	64.9M	29.34M	43.81M	77.81M	98.38M	33.59M
R&D % of Revenue	-	-	23.64%	6.24%	15.35%	4.53%	6.48%	2.62%	3.15%	1.79%
Other Operating Expenses	0	488K	0	0	0	2.39M	24.34M	4.7M	-18.96M	102.07M
Operating Income+	-20.67M	-48.57M	-72.42M	-135.41M	-111.06M	-50.91M	-89.72M	-89.85M	-97.36M	-141.93M
Operating Margin %	-	-	-43.03%	-13.42%	-26.27%	-7.85%	-13.27%	-3.02%	-3.12%	-7.58%
Operating Income Growth %	-1.42%	-1.35%	-0.49%	-0.87%	0.18%	0.54%	-0.76%	-0%	-0.08%	-0.46%
EBITDA+	-20.58M	-48.45M	-72.02M	-134.09M	-109.47M	-49.59M	-88.8M	-89.06M	-96.49M	-141.13M
EBITDA Margin %	-	-	-42.79%	-13.29%	-25.9%	-7.65%	-13.13%	-2.99%	-3.09%	-7.54%
EBITDA Growth %	-1.41%	-1.35%	-0.49%	-0.86%	0.18%	0.55%	-0.79%	-0%	-0.08%	-0.46%
D&A (Non-Cash Add-back)	90K	120K	402K	1.32M	1.59M	1.32M	923K	797K	863K	807K
EBIT	-20.56M	-48.35M	-53.36M	-84.78M	-91.82M	-48.52M	-65.38M	-85.15M	-116.31M	-52.53M
Net Interest Income+	0	0	0	0	0	0	0	0	0	7.95M
Interest Income	104K	0	0	0	0	0	0	0	0	7.95M
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	104K	488K	-15.99M	2.68M	-2.48M	-424K	-1.14M	2.95M	8.51M	9.87M
Pretax Income+	-20.56M	-48.08M	-70.35M	-132.74M	-113.54M	-51.34M	-90.86M	-86.91M	-88.85M	-132.06M
Pretax Margin %	-	-	-41.8%	-13.15%	-26.86%	-7.92%	-13.44%	-2.92%	-2.84%	-7.05%
Income Tax+	-90K	-120K	-1.83M	2.68M	0	-182K	0	0	-367K	0
Effective Tax Rate %	1%	1%	0.97%	1%	1.42%	0.99%	1%	1%	1%	1%
Net Income+	-20.56M	-48.08M	-68.52M	-132.74M	-161.35M	-51.02M	-90.86M	-86.91M	-88.48M	-132.06M
Net Margin %	-	-	-40.71%	-13.15%	-38.17%	-7.87%	-13.44%	-2.92%	-2.83%	-7.05%
Net Income Growth %	-1.41%	-1.34%	-0.43%	-0.94%	-0.22%	0.68%	-0.78%	0.04%	-0.02%	-0.49%
Net Income (Continuing)	-20.56M	-48.08M	-50.46M	-82.1M	-113.54M	-51.15M	-90.86M	-86.91M	-88.48M	-132.06M
Discontinued Operations	0	0	0	0	0	139K	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.10	-2.25	-2.44	-4.03	-3.46	-1.20	-1.60	-1.33	-1.27	-1.71
EPS Growth %	-0.38%	-1.05%	-0.08%	-0.65%	0.14%	0.65%	-0.33%	0.17%	0.05%	-0.35%
EPS (Basic)	-1.10	-2.25	-2.44	-4.03	-3.46	-1.20	-1.60	-1.33	-1.27	-1.71
Diluted Shares Outstanding	18.62M	21.42M	28.1M	32.91M	41.32M	42.54M	56.73M	65.21M	69.81M	77.3M
Basic Shares Outstanding	18.62M	21.42M	28.1M	32.91M	41.32M	42.54M	56.73M	65.21M	69.81M	77.3M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	92.04M	174.13M	208.85M	179.5M	83.8M	57.49M	205.03M	231.55M	128.86M	125.95M
Cash & Short-Term Investments	92.04M	174.13M	208.85M	167.97M	73.27M	54.13M	191.41M	217.57M	119.11M	113.59M
Cash Only	9.85M	30.17M	208.85M	57.02M	34.19M	22.06M	27.35M	45.28M	39.88M	24.57M
Short-Term Investments	75.02M	107.05M	0	110.95M	39.08M	32.07M	164.06M	172.29M	79.23M	89.02M
Accounts Receivable	0	0	481K	563K	704K	772K	623K	484K	298K	318K
Days Sales Outstanding	-	-	104.32	20.36	60.79	43.47	33.63	5.94	3.48	6.2
Inventory	0	0	-6.36M	791K	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	42.15	-	-	-	-	-	-
Other Current Assets	1.66M	1.33M	5.88M	5.37M	6.72M	0	0	13.49M	9.45M	12.04M
Total Non-Current Assets+	2.04M	1.95M	34.66M	96.07M	14.49M	13.29M	46.18M	23.05M	68.55M	94.38M
Property, Plant & Equipment	360K	481K	2.16M	4.28M	2.47M	1.65M	1.33M	1.1M	1.62M	1.01M
Fixed Asset Turnover	-	-	0.78x	2.36x	1.71x	3.92x	5.06x	27.07x	19.29x	18.57x
Goodwill	0	0	18.5M	18.5M	0	0	0	0	0	0
Intangible Assets	0	0	7.35M	72.95M	7.2M	7.12M	7.05M	6.97M	269K	0
Long-Term Investments	7.17M	36.91M	15M	0	0	0	34.24M	12.24M	62.77M	90.3M
Other Non-Current Assets	-5.49M	-35.44M	279K	332K	4.83M	4.51M	3.55M	2.73M	3.89M	3.07M
Total Assets+	94.08M	176.09M	243.51M	275.57M	98.3M	70.78M	251.21M	254.6M	197.41M	220.33M
Asset Turnover	-	-	0.01x	0.04x	0.04x	0.09x	0.03x	0.12x	0.16x	0.08x
Asset Growth %	4.41%	0.87%	0.38%	0.13%	-0.64%	-0.28%	2.55%	0.01%	-0.22%	0.12%
Total Current Liabilities+	1.55M	6.22M	12.76M	27.34M	22.43M	14.87M	22.93M	21.94M	30.95M	31.6M
Accounts Payable	810K	2.85M	7.82M	11.68M	9.92M	5.25M	9.98M	10.35M	8.88M	4.69M
Days Payables Outstanding	3.29K	8.65K	2.37K	622.1	892.65	373.6	773.29	315.9	179.22	613.13
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	1000K
Other Current Liabilities	0	100K	0	7.44M	7.48M	7.08M	6.59M	7.5M	6.11M	11.59M
Current Ratio	59.19x	27.98x	16.37x	6.56x	3.74x	3.87x	8.94x	10.55x	4.16x	3.99x
Quick Ratio	59.19x	27.98x	16.86x	6.54x	3.74x	3.87x	8.94x	10.55x	4.16x	3.99x
Cash Conversion Cycle	-	-	-	-559.59	-	-	-	-	-	-
Total Non-Current Liabilities+	0	372K	5.49M	33.1M	5.95M	18.26M	30.94M	35.04M	9.27M	33.18M
Long-Term Debt	0	0	0	29.91M	0	10.65M	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	549K	549K	549K	367K	367K	367K	0	0
Other Non-Current Liabilities	0	372K	4.94M	2.64M	5.4M	7.24M	30.57M	34.67M	9.27M	13.14M
Total Liabilities	1.55M	6.59M	18.25M	60.44M	28.39M	33.13M	53.87M	56.98M	40.23M	64.77M
Total Debt+	0	0	142K	30.52M	637K	11.26M	693K	684K	426K	0
Net Debt	-9.85M	-30.17M	-208.71M	-26.5M	-33.55M	-10.81M	-26.66M	-44.59M	-39.45M	-24.57M
Debt / Equity	-	-	0.00x	0.14x	0.01x	0.30x	0.00x	0.00x	0.00x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	92.52M	169.49M	225.26M	215.12M	69.91M	37.65M	197.34M	197.62M	157.18M	155.55M
Equity Growth %	5.46%	0.83%	0.33%	-0.05%	-0.68%	-0.46%	4.24%	0%	-0.2%	-0.01%
Book Value per Share	4.97	7.91	8.02	6.54	1.69	0.89	3.48	3.03	2.25	2.01
Total Shareholders' Equity	92.52M	169.49M	225.26M	215.12M	69.91M	37.65M	197.34M	197.62M	157.18M	155.55M
Common Stock	0	0	0	0	0	0	1K	1K	1K	1K
Retained Earnings	-42.83M	-90.91M	-159.44M	-292.17M	-453.53M	-504.54M	-595.41M	-682.32M	-770.8M	-902.86M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-149K	-269K	-246K	-69K	-66K	-94K	-224K	-897K	-106K	97K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-20.37M	-34.6M	-54.66M	-100.81M	-96.44M	-38.63M	-52.13M	-67.57M	-78.33M	-20.07M
Operating CF Margin %	-	-	-32.48%	-9.99%	-22.82%	-5.96%	-7.71%	-2.27%	-2.51%	-1.07%
Operating CF Growth %	-1.67%	-0.7%	-0.58%	-0.84%	0.04%	0.6%	-0.35%	-0.3%	-0.16%	0.74%
Net Income	-20.56M	-48.08M	-68.52M	-132.74M	-113.54M	-51.02M	-90.86M	-86.91M	-88.48M	-132.06M
Depreciation & Amortization	90K	120K	402K	1.88M	1.59M	1.32M	923K	797K	863K	807K
Stock-Based Compensation	891K	6.1M	14.43M	20.05M	0	11.21M	14.06M	15.04M	20.54M	10.86M
Deferred Taxes	289K	216K	-1.84M	0	0	-182K	752K	0	-367K	0
Other Non-Cash Items	-5K	2.78M	10.67M	555K	18.21M	2.39M	24.34M	4.7M	-20.27M	89.41M
Working Capital Changes	-1.07M	4.25M	865K	9.44M	-2.7M	-2.36M	-1.34M	-1.2M	9.39M	10.92M
Change in Receivables	0	0	0	-4.38M	-809K	4.9M	149K	139K	186K	-20K
Change in Inventory	0	0	0	102K	605K	0	0	0	0	0
Change in Payables	-359K	1.81M	4.56M	6.96M	-3.16M	-5.22M	3.65M	368K	-1.47M	-4.19M
Cash from Investing+	-76.95M	-61.9M	-55.69M	9.37M	105.68M	6.39M	-167.63M	12.63M	46.22M	-69.77M
Capital Expenditures	-507K	-232K	-1.24M	-1.36M	-1.61M	-453K	-308K	-605K	-1.31M	-121K
CapEx % of Revenue	-	-	0.73%	0.13%	0.38%	0.07%	0.05%	0.02%	0.04%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-76.44M	-61.67M	-44.81M	77.84M	34.19M	0	-167.32M	13.23M	0	-35.81M
Cash from Financing+	96.41M	116.83M	100.39M	128.26M	-30.32M	18.37M	225.05M	72.87M	26.71M	74.54M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	121K	235K	-1.21M	0	-141K	-1.67M	123K	-8K	-377K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-20.88M	-34.84M	-55.9M	-102.17M	-98.06M	-39.09M	-52.44M	-68.17M	-79.63M	-20.2M
FCF Margin %	-	-	-33.21%	-10.12%	-23.2%	-6.03%	-7.76%	-2.29%	-2.55%	-1.08%
FCF Growth %	-1.59%	-0.67%	-0.6%	-0.83%	0.04%	0.6%	-0.34%	-0.3%	-0.17%	0.75%
FCF per Share	-1.12	-1.63	-1.99	-3.10	-2.37	-0.92	-0.92	-1.05	-1.14	-0.26
FCF Conversion (FCF/Net Income)	0.99x	0.72x	0.80x	0.76x	0.60x	0.76x	0.57x	0.78x	0.89x	0.15x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-57.31%	-36.7%	-34.72%	-60.28%	-113.22%	-94.86%	-77.33%	-44.01%	-49.88%	-84.46%
Return on Invested Capital (ROIC)	-60.6%	-32.82%	-69.7%	-99%	-74.04%	-120.83%	-68.13%	-41.64%	-53.94%	-85.6%
Gross Margin	-	-	28.28%	32.12%	4.07%	20.81%	30.29%	59.8%	42.14%	85.09%
Net Margin	-	-	-4071.48%	-1315.41%	-3817.22%	-787.03%	-1343.96%	-292.11%	-283.15%	-705.48%
Debt / Equity	-	-	0.00x	0.14x	0.01x	0.30x	0.00x	0.00x	0.00x	-
FCF Conversion	0.99x	0.72x	0.80x	0.76x	0.60x	0.76x	0.57x	0.78x	0.89x	0.15x
Revenue Growth	-	-	-	499.58%	-58.11%	53.35%	4.3%	340.05%	5.03%	-40.09%

Revenue by Segment

	2017	2018	2019	2020	2021	2022	2023	2024
License and Service	-	-	-	-	-	25.1M	28.21M	16.18M
License and Service Growth	-	-	-	-	-	-	12.41%	-42.66%
Contract research	-	-	-	-	5.83M	4.39M	3.04M	2.54M
Contract research Growth	-	-	-	-	-	-24.61%	-30.94%	-16.28%
Other	-	-	-	-	-	257K	-	-
Other Growth	-	-	-	-	-	-	-	-
Other revenue	-	-	-	-	931K	-	-	-
Other revenue Growth	-	-	-	-	-	-	-	-
Rhofade Product	-	1.14M	-	424K	-	-	-	-
Rhofade Product Growth	-	-	-	-	-	-	-	-
Product	-	3.94M	-	424K	-	-	-	-
Product Growth	-	-	-	-	-	-	-	-
Laboratory Research Revenue	-	-	4.23M	-	-	-	-	-
Laboratory Research Revenue Growth	-	-	-	-	-	-	-	-
Eskata Product	-	2.8M	-	-	-	-	-	-
Eskata Product Growth	-	-	-	-	-	-	-	-
Contract Research	3.2M	-	-	-	-	-	-	-
Contract Research Growth	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Aclaris Therapeutics, Inc. (ACRS) reported $15.7M in revenue for fiscal year 2024.

Aclaris Therapeutics, Inc. (ACRS) saw revenue decline by 40.1% over the past year.

Aclaris Therapeutics, Inc. (ACRS) reported a net loss of $141.7M for fiscal year 2024.

Dividend & Returns

Aclaris Therapeutics, Inc. (ACRS) has a return on equity (ROE) of -84.5%. Negative ROE indicates the company is unprofitable.

Aclaris Therapeutics, Inc. (ACRS) had negative free cash flow of $78.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Aclaris Therapeutics, Inc. (ACRS) 10-Year Financial Performance & Capital Metrics

ACRS • • Industrial / General

HealthcareDiagnostics & ResearchContract Research & Clinical Trial ServicesResearch Support Services

Revenue $19M -40.1%
EBITDA -$141M -46.3%
Net Income -$132M -49.3%
EPS (Diluted) -1.71 -34.6%
Gross Margin 85.09% +101.9%
EBITDA Margin -753.87% -144.1%
Operating Margin -758.18% -143.4%
Net Margin -705.48% -149.2%
ROE -84.46% -69.3%
ROIC -85.6% -58.7%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 88 (top 12%)
✓Strong 5Y sales CAGR of 34.7%
✓Trading at only 1.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 10.7% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y34.66%

3Y40.42%

TTM-41.87%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-282.88%

EPS CAGR

10Y-

5Y-

3Y-

TTM-164.88%

ROCE

10Y Avg-54.45%

5Y Avg-61.62%

3Y Avg-55.9%

Latest-79.92%

Peer Comparison

Research Support Services

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CRLCharles River Laboratories International, Inc.	11B	223.47	1117.35	-1.92%	-2.07%	-2.42%	4.56%	0.78
SHCSotera Health Company	5.5B	19.35	120.94	4.88%	4.82%	10.07%	0.82%	5.81
ISPCiSpecimen Inc.	4.22M	0.42	-0.02	-6.42%	-343.99%	-375.34%		0.09
NOTVInotiv, Inc.	19.59M	0.57	-0.27	4.54%	-13.38%	-50.45%		3.01
ACRSAclaris Therapeutics, Inc.	289.28M	2.67	-1.56	-40.09%	-9%	-117.97%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	1.68M	10.09M	4.23M	6.48M	6.76M	29.75M	31.25M	18.72M
Revenue Growth %	-	-	-	5%	-0.58%	0.53%	0.04%	3.4%	0.05%	-0.4%
Cost of Goods Sold+	90K	120K	1.21M	6.85M	4.05M	5.13M	4.71M	11.96M	18.08M	2.79M
COGS % of Revenue	-	-	0.72%	0.68%	0.96%	0.79%	0.7%	0.4%	0.58%	0.15%
Gross Profit+	-90K	-120K	476K	3.24M	172K	1.35M	2.05M	17.79M	13.17M	15.93M
Gross Margin %	-	-	0.28%	0.32%	0.04%	0.21%	0.3%	0.6%	0.42%	0.85%
Gross Profit Growth %	-	-0.33%	4.97%	5.81%	-0.95%	6.84%	0.52%	7.69%	-0.26%	0.21%
Operating Expenses+	20.67M	48.57M	72.9M	138.66M	92.73M	52.26M	91.77M	107.65M	110.53M	157.86M
OpEx % of Revenue	-	-	43.31%	13.74%	21.94%	8.06%	13.57%	3.62%	3.54%	8.43%
Selling, General & Admin	5.33M	15.09M	33.11M	75.65M	27.83M	20.53M	23.62M	25.13M	31.1M	22.2M
SG&A % of Revenue	-	-	19.67%	7.5%	6.58%	3.17%	3.49%	0.84%	1%	1.19%
Research & Development	15.34M	33.48M	39.79M	63.01M	64.9M	29.34M	43.81M	77.81M	98.38M	33.59M
R&D % of Revenue	-	-	23.64%	6.24%	15.35%	4.53%	6.48%	2.62%	3.15%	1.79%
Other Operating Expenses	0	488K	0	0	0	2.39M	24.34M	4.7M	-18.96M	102.07M
Operating Income+	-20.67M	-48.57M	-72.42M	-135.41M	-111.06M	-50.91M	-89.72M	-89.85M	-97.36M	-141.93M
Operating Margin %	-	-	-43.03%	-13.42%	-26.27%	-7.85%	-13.27%	-3.02%	-3.12%	-7.58%
Operating Income Growth %	-1.42%	-1.35%	-0.49%	-0.87%	0.18%	0.54%	-0.76%	-0%	-0.08%	-0.46%
EBITDA+	-20.58M	-48.45M	-72.02M	-134.09M	-109.47M	-49.59M	-88.8M	-89.06M	-96.49M	-141.13M
EBITDA Margin %	-	-	-42.79%	-13.29%	-25.9%	-7.65%	-13.13%	-2.99%	-3.09%	-7.54%
EBITDA Growth %	-1.41%	-1.35%	-0.49%	-0.86%	0.18%	0.55%	-0.79%	-0%	-0.08%	-0.46%
D&A (Non-Cash Add-back)	90K	120K	402K	1.32M	1.59M	1.32M	923K	797K	863K	807K
EBIT	-20.56M	-48.35M	-53.36M	-84.78M	-91.82M	-48.52M	-65.38M	-85.15M	-116.31M	-52.53M
Net Interest Income+	0	0	0	0	0	0	0	0	0	7.95M
Interest Income	104K	0	0	0	0	0	0	0	0	7.95M
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	104K	488K	-15.99M	2.68M	-2.48M	-424K	-1.14M	2.95M	8.51M	9.87M
Pretax Income+	-20.56M	-48.08M	-70.35M	-132.74M	-113.54M	-51.34M	-90.86M	-86.91M	-88.85M	-132.06M
Pretax Margin %	-	-	-41.8%	-13.15%	-26.86%	-7.92%	-13.44%	-2.92%	-2.84%	-7.05%
Income Tax+	-90K	-120K	-1.83M	2.68M	0	-182K	0	0	-367K	0
Effective Tax Rate %	1%	1%	0.97%	1%	1.42%	0.99%	1%	1%	1%	1%
Net Income+	-20.56M	-48.08M	-68.52M	-132.74M	-161.35M	-51.02M	-90.86M	-86.91M	-88.48M	-132.06M
Net Margin %	-	-	-40.71%	-13.15%	-38.17%	-7.87%	-13.44%	-2.92%	-2.83%	-7.05%
Net Income Growth %	-1.41%	-1.34%	-0.43%	-0.94%	-0.22%	0.68%	-0.78%	0.04%	-0.02%	-0.49%
Net Income (Continuing)	-20.56M	-48.08M	-50.46M	-82.1M	-113.54M	-51.15M	-90.86M	-86.91M	-88.48M	-132.06M
Discontinued Operations	0	0	0	0	0	139K	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.10	-2.25	-2.44	-4.03	-3.46	-1.20	-1.60	-1.33	-1.27	-1.71
EPS Growth %	-0.38%	-1.05%	-0.08%	-0.65%	0.14%	0.65%	-0.33%	0.17%	0.05%	-0.35%
EPS (Basic)	-1.10	-2.25	-2.44	-4.03	-3.46	-1.20	-1.60	-1.33	-1.27	-1.71
Diluted Shares Outstanding	18.62M	21.42M	28.1M	32.91M	41.32M	42.54M	56.73M	65.21M	69.81M	77.3M
Basic Shares Outstanding	18.62M	21.42M	28.1M	32.91M	41.32M	42.54M	56.73M	65.21M	69.81M	77.3M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	92.04M	174.13M	208.85M	179.5M	83.8M	57.49M	205.03M	231.55M	128.86M	125.95M
Cash & Short-Term Investments	92.04M	174.13M	208.85M	167.97M	73.27M	54.13M	191.41M	217.57M	119.11M	113.59M
Cash Only	9.85M	30.17M	208.85M	57.02M	34.19M	22.06M	27.35M	45.28M	39.88M	24.57M
Short-Term Investments	75.02M	107.05M	0	110.95M	39.08M	32.07M	164.06M	172.29M	79.23M	89.02M
Accounts Receivable	0	0	481K	563K	704K	772K	623K	484K	298K	318K
Days Sales Outstanding	-	-	104.32	20.36	60.79	43.47	33.63	5.94	3.48	6.2
Inventory	0	0	-6.36M	791K	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	42.15	-	-	-	-	-	-
Other Current Assets	1.66M	1.33M	5.88M	5.37M	6.72M	0	0	13.49M	9.45M	12.04M
Total Non-Current Assets+	2.04M	1.95M	34.66M	96.07M	14.49M	13.29M	46.18M	23.05M	68.55M	94.38M
Property, Plant & Equipment	360K	481K	2.16M	4.28M	2.47M	1.65M	1.33M	1.1M	1.62M	1.01M
Fixed Asset Turnover	-	-	0.78x	2.36x	1.71x	3.92x	5.06x	27.07x	19.29x	18.57x
Goodwill	0	0	18.5M	18.5M	0	0	0	0	0	0
Intangible Assets	0	0	7.35M	72.95M	7.2M	7.12M	7.05M	6.97M	269K	0
Long-Term Investments	7.17M	36.91M	15M	0	0	0	34.24M	12.24M	62.77M	90.3M
Other Non-Current Assets	-5.49M	-35.44M	279K	332K	4.83M	4.51M	3.55M	2.73M	3.89M	3.07M
Total Assets+	94.08M	176.09M	243.51M	275.57M	98.3M	70.78M	251.21M	254.6M	197.41M	220.33M
Asset Turnover	-	-	0.01x	0.04x	0.04x	0.09x	0.03x	0.12x	0.16x	0.08x
Asset Growth %	4.41%	0.87%	0.38%	0.13%	-0.64%	-0.28%	2.55%	0.01%	-0.22%	0.12%
Total Current Liabilities+	1.55M	6.22M	12.76M	27.34M	22.43M	14.87M	22.93M	21.94M	30.95M	31.6M
Accounts Payable	810K	2.85M	7.82M	11.68M	9.92M	5.25M	9.98M	10.35M	8.88M	4.69M
Days Payables Outstanding	3.29K	8.65K	2.37K	622.1	892.65	373.6	773.29	315.9	179.22	613.13
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	1000K
Other Current Liabilities	0	100K	0	7.44M	7.48M	7.08M	6.59M	7.5M	6.11M	11.59M
Current Ratio	59.19x	27.98x	16.37x	6.56x	3.74x	3.87x	8.94x	10.55x	4.16x	3.99x
Quick Ratio	59.19x	27.98x	16.86x	6.54x	3.74x	3.87x	8.94x	10.55x	4.16x	3.99x
Cash Conversion Cycle	-	-	-	-559.59	-	-	-	-	-	-
Total Non-Current Liabilities+	0	372K	5.49M	33.1M	5.95M	18.26M	30.94M	35.04M	9.27M	33.18M
Long-Term Debt	0	0	0	29.91M	0	10.65M	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	549K	549K	549K	367K	367K	367K	0	0
Other Non-Current Liabilities	0	372K	4.94M	2.64M	5.4M	7.24M	30.57M	34.67M	9.27M	13.14M
Total Liabilities	1.55M	6.59M	18.25M	60.44M	28.39M	33.13M	53.87M	56.98M	40.23M	64.77M
Total Debt+	0	0	142K	30.52M	637K	11.26M	693K	684K	426K	0
Net Debt	-9.85M	-30.17M	-208.71M	-26.5M	-33.55M	-10.81M	-26.66M	-44.59M	-39.45M	-24.57M
Debt / Equity	-	-	0.00x	0.14x	0.01x	0.30x	0.00x	0.00x	0.00x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	92.52M	169.49M	225.26M	215.12M	69.91M	37.65M	197.34M	197.62M	157.18M	155.55M
Equity Growth %	5.46%	0.83%	0.33%	-0.05%	-0.68%	-0.46%	4.24%	0%	-0.2%	-0.01%
Book Value per Share	4.97	7.91	8.02	6.54	1.69	0.89	3.48	3.03	2.25	2.01
Total Shareholders' Equity	92.52M	169.49M	225.26M	215.12M	69.91M	37.65M	197.34M	197.62M	157.18M	155.55M
Common Stock	0	0	0	0	0	0	1K	1K	1K	1K
Retained Earnings	-42.83M	-90.91M	-159.44M	-292.17M	-453.53M	-504.54M	-595.41M	-682.32M	-770.8M	-902.86M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-149K	-269K	-246K	-69K	-66K	-94K	-224K	-897K	-106K	97K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-20.37M	-34.6M	-54.66M	-100.81M	-96.44M	-38.63M	-52.13M	-67.57M	-78.33M	-20.07M
Operating CF Margin %	-	-	-32.48%	-9.99%	-22.82%	-5.96%	-7.71%	-2.27%	-2.51%	-1.07%
Operating CF Growth %	-1.67%	-0.7%	-0.58%	-0.84%	0.04%	0.6%	-0.35%	-0.3%	-0.16%	0.74%
Net Income	-20.56M	-48.08M	-68.52M	-132.74M	-113.54M	-51.02M	-90.86M	-86.91M	-88.48M	-132.06M
Depreciation & Amortization	90K	120K	402K	1.88M	1.59M	1.32M	923K	797K	863K	807K
Stock-Based Compensation	891K	6.1M	14.43M	20.05M	0	11.21M	14.06M	15.04M	20.54M	10.86M
Deferred Taxes	289K	216K	-1.84M	0	0	-182K	752K	0	-367K	0
Other Non-Cash Items	-5K	2.78M	10.67M	555K	18.21M	2.39M	24.34M	4.7M	-20.27M	89.41M
Working Capital Changes	-1.07M	4.25M	865K	9.44M	-2.7M	-2.36M	-1.34M	-1.2M	9.39M	10.92M
Change in Receivables	0	0	0	-4.38M	-809K	4.9M	149K	139K	186K	-20K
Change in Inventory	0	0	0	102K	605K	0	0	0	0	0
Change in Payables	-359K	1.81M	4.56M	6.96M	-3.16M	-5.22M	3.65M	368K	-1.47M	-4.19M
Cash from Investing+	-76.95M	-61.9M	-55.69M	9.37M	105.68M	6.39M	-167.63M	12.63M	46.22M	-69.77M
Capital Expenditures	-507K	-232K	-1.24M	-1.36M	-1.61M	-453K	-308K	-605K	-1.31M	-121K
CapEx % of Revenue	-	-	0.73%	0.13%	0.38%	0.07%	0.05%	0.02%	0.04%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-76.44M	-61.67M	-44.81M	77.84M	34.19M	0	-167.32M	13.23M	0	-35.81M
Cash from Financing+	96.41M	116.83M	100.39M	128.26M	-30.32M	18.37M	225.05M	72.87M	26.71M	74.54M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	121K	235K	-1.21M	0	-141K	-1.67M	123K	-8K	-377K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-20.88M	-34.84M	-55.9M	-102.17M	-98.06M	-39.09M	-52.44M	-68.17M	-79.63M	-20.2M
FCF Margin %	-	-	-33.21%	-10.12%	-23.2%	-6.03%	-7.76%	-2.29%	-2.55%	-1.08%
FCF Growth %	-1.59%	-0.67%	-0.6%	-0.83%	0.04%	0.6%	-0.34%	-0.3%	-0.17%	0.75%
FCF per Share	-1.12	-1.63	-1.99	-3.10	-2.37	-0.92	-0.92	-1.05	-1.14	-0.26
FCF Conversion (FCF/Net Income)	0.99x	0.72x	0.80x	0.76x	0.60x	0.76x	0.57x	0.78x	0.89x	0.15x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-57.31%	-36.7%	-34.72%	-60.28%	-113.22%	-94.86%	-77.33%	-44.01%	-49.88%	-84.46%
Return on Invested Capital (ROIC)	-60.6%	-32.82%	-69.7%	-99%	-74.04%	-120.83%	-68.13%	-41.64%	-53.94%	-85.6%
Gross Margin	-	-	28.28%	32.12%	4.07%	20.81%	30.29%	59.8%	42.14%	85.09%
Net Margin	-	-	-4071.48%	-1315.41%	-3817.22%	-787.03%	-1343.96%	-292.11%	-283.15%	-705.48%
Debt / Equity	-	-	0.00x	0.14x	0.01x	0.30x	0.00x	0.00x	0.00x	-
FCF Conversion	0.99x	0.72x	0.80x	0.76x	0.60x	0.76x	0.57x	0.78x	0.89x	0.15x
Revenue Growth	-	-	-	499.58%	-58.11%	53.35%	4.3%	340.05%	5.03%	-40.09%

Revenue by Segment

	2017	2018	2019	2020	2021	2022	2023	2024
License and Service	-	-	-	-	-	25.1M	28.21M	16.18M
License and Service Growth	-	-	-	-	-	-	12.41%	-42.66%
Contract research	-	-	-	-	5.83M	4.39M	3.04M	2.54M
Contract research Growth	-	-	-	-	-	-24.61%	-30.94%	-16.28%
Other	-	-	-	-	-	257K	-	-
Other Growth	-	-	-	-	-	-	-	-
Other revenue	-	-	-	-	931K	-	-	-
Other revenue Growth	-	-	-	-	-	-	-	-
Rhofade Product	-	1.14M	-	424K	-	-	-	-
Rhofade Product Growth	-	-	-	-	-	-	-	-
Product	-	3.94M	-	424K	-	-	-	-
Product Growth	-	-	-	-	-	-	-	-
Laboratory Research Revenue	-	-	4.23M	-	-	-	-	-
Laboratory Research Revenue Growth	-	-	-	-	-	-	-	-
Eskata Product	-	2.8M	-	-	-	-	-	-
Eskata Product Growth	-	-	-	-	-	-	-	-
Contract Research	3.2M	-	-	-	-	-	-	-
Contract Research Growth	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Aclaris Therapeutics, Inc. (ACRS) reported $15.7M in revenue for fiscal year 2024.

Aclaris Therapeutics, Inc. (ACRS) saw revenue decline by 40.1% over the past year.

Aclaris Therapeutics, Inc. (ACRS) reported a net loss of $141.7M for fiscal year 2024.

Dividend & Returns

Aclaris Therapeutics, Inc. (ACRS) has a return on equity (ROE) of -84.5%. Negative ROE indicates the company is unprofitable.

Aclaris Therapeutics, Inc. (ACRS) had negative free cash flow of $78.8M in fiscal year 2024, likely due to heavy capital investments.